The Effects of Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients
Launched by THE QUEEN ELIZABETH HOSPITAL · Sep 25, 2013
Trial Information
Current as of June 18, 2025
Unknown status
Keywords
ClinConnect Summary
Methods
The study will be conducted using randomized controlled trial.
Sampling
The subjects will be the patients with Tenckhoff Catheter recruited from the renal team in a regional acute hospital and a satellite dialysis centre. The sampling method will be convenience sampling. The subjects will be recruited sequentially after the insertion of Tenckhoff Catheter.
Inclusion criteria
* Patient with established Tenckhoff Catheter for at least 3 months
* Patient with skin condition healed satisfactorily
Exclusion criteria
* Patient presents with signs and symptoms of exit site infection...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Patient with established Tenckhoff Catheter for at least 3 months with skin healed satisfactorily
- Exclusion Criteria:
- • Patient presents with signs and symptoms of exit site infection e.g. purulent discharge, pain, and swab of exit cultured with positive growth.
- • Patient with unhealed exit site.
- • Patient currently requires antibiotics
- • Patient shows sensitive to JUC Spray Dressing or 0.05% Chlorhexidine solution
About The Queen Elizabeth Hospital
The Queen Elizabeth Hospital, a leading healthcare institution, is dedicated to advancing medical research and improving patient outcomes through innovative clinical trials. With a strong emphasis on patient safety and ethical standards, the hospital collaborates with multidisciplinary teams to explore cutting-edge therapies and treatments across various medical fields. Committed to fostering scientific excellence, the Queen Elizabeth Hospital aims to translate research findings into practical applications that enhance healthcare delivery and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials